scholarly journals Prognostic Value of CD133 and SOX2 in Advanced Cancer

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Susu Han ◽  
Tao Huang ◽  
Xing Wu ◽  
Xiyu Wang ◽  
Shanshan Liu ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Advanced Cancer ◽  
Prognostic Value ◽  
Multivariable Analysis ◽  
Disease Free Survival ◽  
Molecular Therapy ◽  
Chinese Patients ◽  
Advanced Cancer Patients ◽  
Free Survival ◽  
Stratified Analysis

Background. The prognostic value of CD133 and SOX2 expression in advanced cancer remains unclear. This study was first conducted to investigate the association between CD133 or SOX2 positivity and clinical outcomes for advanced cancer patients.Methods. Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated to evaluate the correlation between CD133 or SOX2 positivity and overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), cancer-specific survival (CSS), or recurrence-free survival (RFS) from multivariable analysis. Trial sequential analysis (TSA) was also performed.Results. 13 studies with 1358 cases (CD133) and five studies with 433 cases (SOX2) were identified. CD133 positivity was correlated with worse CSS and OS, but there was no correlation between CD133 positivity and DFS. SOX2 positivity was associated with poor DFS and RFS but was not linked to PFS. Stratified analysis by study source showed that only CD133 positivity can decrease OS for Chinese patients. Stratified analysis by treatment regimens indicated that CD133 positivity was linked to poor OS in patients treated with adjuvant therapy. TSA showed that additional studies were necessary.Conclusions. CD133 and SOX2 might be associated with worse prognosis in advanced cancer. More prospective studies are strongly needed.Impact. CD133 and SOX2 may be promising targeted molecular therapy for advanced cancer patients.

scholarly journals Prognostic value of ALDH1 and Nestin in advanced cancer: a systematic meta-analysis with trial sequential analysis

2019 ◽  
Vol 11 ◽  
pp. 175883591983083 ◽  
Author(s):  
Susu Han ◽  
Tao Huang ◽  
Xing Wu ◽  
Xiyu Wang ◽  
Wen Li ◽  
...  
Keyword(s):  
Survival Rate ◽  
Advanced Cancer ◽  
Subgroup Analysis ◽  
Sequential Analysis ◽  
Multivariable Analysis ◽  
Chinese Patients ◽  
Trial Sequential Analysis ◽  
Tumor Type ◽  
Term Survival ◽  
Free Survival

Background: Novel prognostic markers and therapeutic targets for advanced cancer are urgently needed. This report with trial sequential analysis (TSA) was first conducted to provide robust estimates of the correlation between aldehyde dehydrogenase 1 (ALDH1) and Nestin and clinical outcomes of advanced cancer patients. Methods: Hazard ratios (HRs) with 95% confidence intervals (CIs) were summarized for overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), cancer-specific survival (CSS), relapse/recurrence-free survival (RFS), and metastasis-free survival (MFS) from multivariable analysis. TSA was performed to control for random errors. Results: A total of 20 studies with 2050 patients (ALDH1: 15 studies with 1557 patients and Nestin: 5 studies with 493 patients) were identified. ALDH1 (HR = 2.28, p < 0.001) and Nestin (HR = 2.39, p < 0.001) were associated with a worse OS, as confirmed by TSA. Nestin positivity was linked to a poor PFS (HR = 2.08, p < 0.001), but ALDH1 was not linked to DFS, RFS, MFS, or PFS, and TSA showed that more studies were needed. Subgroup analysis by tumor type indicated that ALDH1 positivity may be associated with shorter OS in breast, head and neck cancers, but there was no association with colorectal cancer. Subgroup analysis by study source showed that ALDH1 positivity was correlated with a worse OS for Japanese (HR = 1.94, p = 0.002) and European patients (HR = 4.15, p < 0.001), but there was no association for Chinese patients. Subgroup analysis by survival rate showed that ALDH1 positivity correlated with poor OS at ⩾ 5 years (HR = 2.33, p < 0.001) or 10 years (HR = 1.76, p = 0.038). Conclusions: ALDH1 may be more valuable as an effective therapeutic target than Nestin for improving the long-term survival rate of advanced cancer. Additional prospective clinical trials are needed across different cancer types.

scholarly journals The prognostic value of hypoxia-inducible factor-1α in advanced cancer survivors: a meta-analysis with trial sequential analysis

2019 ◽  
Vol 11 ◽  
pp. 175883591987585 ◽  
Author(s):  
Susu Han ◽  
Tao Huang ◽  
Fenggang Hou ◽  
Liting Yao ◽  
Xiyu Wang ◽  
...  
Keyword(s):  
Advanced Cancer ◽  
Sequential Analysis ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Progression Free Survival ◽  
Trial Sequential Analysis ◽  
Advanced Cancer Patients ◽  
Cancer Specific Survival ◽  
Study Region ◽  
Free Survival

Background: Expression of hypoxia-inducible factors (HIFs) has been observed, but their prognostic role in advanced cancers remains uncertain. We conducted a meta-analysis to establish the prognostic effect of HIFs and to better guide treatment planning for advanced cancers. Methods: Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. Trial sequential analysis (TSA) was also performed. The clinical outcomes included overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), cancer-specific survival (CSS), relapse/recurrence-free survival (RFS), and metastasis-free survival (MFS) in patients with advanced tumors according to multivariate analysis. Results: A total of 31 studies including 3453 cases who received chemotherapy, radiotherapy, or chemoradiotherapy were identified. Pooled analyses revealed that HIF-1α expression was correlated with worse OS (HR = 1.61, p < 0.001), DFS (HR = 1.61, p < 0.001), PFS (HR = 1.49, p = 0.01), CSS (HR = 1.65, p = 0.056), RFS (HR = 2.10, p = 0.015), or MFS (HR = 2.36, p = 0.002) in advanced cancers. HIF-1α expression was linked to shorter OS in the digestive tract, epithelial ovarian, breast, non-small cell lung, and clear cell renal cell carcinomas. Subgroup analysis by study region showed that HIF-1α expression was correlated with poor OS in Europeans and Asians, while an analysis by histologic subtypes found that HIF-1α expression was not associated with OS in squamous cell carcinoma. No relationship was found between HIF-2α expression and OS, DFS, PFS, or CSS. Conclusions: Targeting HIF-1α may be a useful therapeutic approach to improve survival for advanced cancer patients. Based on TSA, more randomized controlled trials are strongly suggested.

scholarly journals Prognostic value of pretreatment platelet counts in lung cancer: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Yuan Yuan ◽  
Hai Zhong ◽  
Liang Ye ◽  
Qian Li ◽  
rong su Fang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Publication Bias ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Cochrane Library ◽  
Free Survival ◽  
Lung Cancer Patients ◽  
Platelet Counts

Abstract Background : The prognostic value of elevated pretreatment platelet counts remains controversial in lung cancer patients. We performed the present meta-analysis to determine its precise role in these patients. Methods: We employed a multiple search strategy in the PubMed, EMBASE and Cochrane Library databases to identify eligible studies. Disease-free survival (DFS)/progression-free survival (PFS)/time to progression (TTP) and overall survival (OS) were used as outcomes with hazard ratios (HRs) and 95% confidence intervals (CIs). Heterogeneity among the studies and publication bias were also evaluated. Results : A total of 40 studies including 16696 lung cancer patients were eligible for the analysis. Overall, the pooled analysis showed that compared with normal platelet counts, elevated pretreatment platelet counts were associated with poorer OS (HR= 1.54, 95% CI: 1.37-1.72, P<0.001) and poorer DFS/PFS/TTP (HR=1.62, 95% CI: 1.33-1.98, P<0.001) in patients with lung cancer. In subgroup analyses, elevated pretreatment platelet counts were also associated with poorer OS and DFS/PFS/TTP in most subgroups. There was no evidence of publication bias. Conclusions : This meta-analysis revealed that elevated pretreatment platelet counts were an independent predictor of OS and DFS/PFS/TTP in lung cancer patients. Large-scale prospective studies and a validation study are warranted.

scholarly journals Prognostic value of platelet count in lung cancer: a systematic review and meta-analysis

2019 ◽  
Author(s):  
Yuan Yuan ◽  
Hai Zhong ◽  
Liang Ye ◽  
Qian Li ◽  
Rong Su Fang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Platelet Count ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Cochrane Library ◽  
Free Survival ◽  
Lung Cancer Patients ◽  
Pubmed Database

Abstract Background : The prognostic value of pretreatment elevated platelet count remains controversial in lung cancer patients. We performed the present meta-analysis to determine the precise role of it in these patients.Methods: We performed a multiple search strategy in PubMed database, EMBASE and Cochrane Library to identify eligible studies. Disease-free survival (DFS) /Progress-free survival (PFS)/Time to progress(TTP) and Overall survival (OS) were used as outcomes with hazard ratio (HR) and its 95% confidence intervals (CIs). Heterogeneity among studies and publication bias were also evaluated.Results : A total of 39 studies including 16696 lung cancer patients were eligible in the analysis. Overall, the pooled analysis showed that pretreatment elevated platelet count was associated with poorer OS (HR= 1.47, 95%CI: 1.31-1.66, P<0.001) and poorer DFS/PFS/TTP ((HR=1.63, 95%CI: 1.28-2.09, P<0.001) in patients with lung cancer compared with normal platelet count. In subgroup analyses, pretreatment elevated platelet count was also associated with poorer OS and DFS/PFS/TTP in most subgroups. There was no evidence of publication bias.Conclusions : This meta-analysis revealed that pretreatment elevated platelet count was an independent predictor of OS and DFS/PFS/TTP in lung cancer patients. Large scale prospective studies and a validation study are warranted.

scholarly journals Impact of the timing of tumor assessments on median progression-free survival in clinical trials in advanced cancer patients

ESMO Open ◽  
2022 ◽  
Vol 7 (1) ◽  
pp. 100366
Author(s):  
T. Samaille ◽  
C. Moreau Bachelard ◽  
E. Coquan ◽  
P. du Rusquec ◽  
X. Paoletti ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Progression Free Survival ◽  
Advanced Cancer Patients ◽  
Free Survival ◽  
Median Progression Free Survival

Training for awareness of one's own spirituality: A key factor in overcoming barriers to the provision of spiritual care to advanced cancer patients by doctors and nurses

2018 ◽  
Vol 17 (03) ◽  
pp. 345-352 ◽  
Author(s):  
Gil Bar-Sela ◽  
Michael J. Schultz ◽  
Karima Elshamy ◽  
Maryam Rassouli ◽  
Eran Ben-Arye ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Advanced Cancer ◽  
Spiritual Care ◽  
Cultural Context ◽  
Multivariable Analysis ◽  
Perceived Barriers ◽  
Care Provision ◽  
Religion And Spirituality ◽  
Advanced Cancer Patients ◽  
Key Factor

AbstractObjectiveWhen patients feel spiritually supported by staff, we find increased use of hospice and reduced use of aggressive treatments at end of life, yet substantial barriers to staff spiritual care provision still exist. We aimed to study these barriers in a new cultural context and analyzed a new subgroup with “unrealized potential” for improved spiritual care provision: those who are positively inclined toward spiritual care yet do not themselves provide it.MethodWe distributed the Religion and Spirituality in Cancer Care Study via the Middle East Cancer Consortium to physicians and nurses caring for advanced cancer patients. Survey items included how often spiritual care should be provided, how often respondents themselves provide it, and perceived barriers to spiritual care provision.ResultWe had 770 respondents (40% physicians, 60% nurses) from 14 Middle Eastern countries. The results showed that 82% of respondents think staff should provide spiritual care at least occasionally, but 44% provide spiritual care less often than they think they should. In multivariable analysis of respondents who valued spiritual care yet did not themselves provide it to their most recent patients, predictors included low personal sense of being spiritual (p&lt; 0.001) and not having received training (p= 0.02; only 22% received training). How “developed” a country is negatively predicted spiritual care provision (p&lt; 0.001). Self-perceived barriers were quite similar across cultures.Significance of resultsDespite relatively high levels of spiritual care provision, we see a gap between desirability and actual provision. Seeing oneself as not spiritual or only slightly spiritual is a key factor demonstrably associated with not providing spiritual care. Efforts to increase spiritual care provision should target those in favor of spiritual care provision, promoting training that helps participants consider their own spirituality and the role that it plays in their personal and professional lives.

scholarly journals The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis

2021 ◽  
Vol 10 ◽  
Author(s):  
Pei Huang ◽  
Wei Hu ◽  
Ying Zhu ◽  
Yushen Wu ◽  
Huapeng Lin
Keyword(s):  
Cancer Patients ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Progression Free Survival ◽  
Dynamic Monitoring ◽  
Survival Prognosis ◽  
Free Survival ◽  
Programmed Death Ligand 1 ◽  
Programmed Death

BackgroundStudies on the prognostic value of the soluble programmed death ligand 1 (sPD-L1) in cancer patients have not yielded consistent results.ObjectiveThis meta-analysis was performed to assess the association between sPD-L1 and the prognosis of cancer patients.MethodsPublished articles in Pubmed, EMBASE, and Cochrane clinical trial databases were searched from the inception to September 2020. Overall survival (OS), progression-free survival (PFS), recurrence-free survival (RFS), and disease-free survival (DFS) data were evaluated using a hazard ratio (HR) at 95% confidence interval (95% CI).ResultsA total 31 studies involving 17 tumors and 3,780 patients were included. The overexpression of sPD-L1 was associated with shorter OS (HR 1.85, 95% CI 1.59–2.15, I2 = 33%). High sPD-L1 had worse PFS (HR 2.40, 95% CI 1.55–3.72, I2 = 83%), and worse DFS (HR 2.92, 95% CI 2.02–4.29, I2 = 40%), without significant statistical difference in RFS (HR 2.08, 95% CI 0.99–4.40, I2 = 0%).ConclusionsHigh sPD-L1 levels were associated with worse survival prognosis in cancer patients. The sPD-L1 may be a potential prognostic, non-invasive, and dynamic monitoring biomarker for cancers in the future.

scholarly journals Prognostic value of pretreatment platelet counts in lung cancer: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Yuan Yuan ◽  
Hai Zhong ◽  
Liang Ye ◽  
Qian Li ◽  
rong su Fang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Publication Bias ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Cochrane Library ◽  
Free Survival ◽  
Lung Cancer Patients ◽  
Platelet Counts

Abstract Background : The prognostic value of elevated pretreatment platelet counts remains controversial in lung cancer patients. We performed the present meta-analysis to determine its precise role in these patients. Methods: We employed a multiple search strategy in the PubMed, EMBASE and Cochrane Library databases to identify eligible studies. Disease-free survival (DFS)/progression-free survival (PFS)/time to progression (TTP) and overall survival (OS) were used as outcomes with hazard ratios (HRs) and 95% confidence intervals (CIs). Heterogeneity among the studies and publication bias were also evaluated. Results : A total of 40 studies including 16696 lung cancer patients were eligible for the analysis. Overall, the pooled analysis showed that compared with normal platelet counts, elevated pretreatment platelet counts were associated with poorer OS (HR= 1.54, 95% CI: 1.37-1.72, P<0.001) and poorer DFS/PFS/TTP (HR=1.62, 95% CI: 1.33-1.98, P<0.001) in patients with lung cancer. In subgroup analyses, elevated pretreatment platelet counts were also associated with poorer OS and DFS/PFS/TTP in most subgroups. There was no evidence of publication bias. Conclusions : This meta-analysis revealed that elevated pretreatment platelet counts were an independent predictor of OS and DFS/PFS/TTP in lung cancer patients. Large-scale prospective studies and a validation study are warranted.

Sign in / Sign up

Export Citation Format

Share Document